Korean J Gastroenterol.  2023 Feb;81(2):104-107. 10.4166/kjg.2022.150.

Establishment of Hepatocellular Carcinoma Risk Prediction Model in Chronic Hepatitis B Patients with Hepatitis B Surface Antigen Seroclearance

• Nam H

• KMID: 2539581
• DOI: http://doi.org/10.4166/kjg.2022.150

Reference

1. Yang H, Bae SH, Nam H, et al. 2022; A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol. 77:632–641. DOI: 10.1016/j.jhep.2022.03.032. PMID: 35398462.

2. Newsome PN, Cramb R, Davison SM, et al. 2018; Guidelines on the management of abnormal liver blood tests. Gut. 67:6–19. DOI: 10.1136/gutjnl-2017-314924. PMID: 29122851. PMCID: PMC5754852.

3. Korean Association for the Study of the Liver (KASL). 2022; KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 28:276–331. Erratum in: Clin Mol Hepatol 2022;28:940. DOI: 10.3350/cmh.2022.0084.e1. PMID: 36068669. PMCID: PMC9597234.

4. Liu J, Yang HI, Lee MH, et al. REVEAL-HBV Study Group. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010; 139:474–482. DOI: 10.1053/j.gastro.2010.04.048. PMID: 20434450.

5. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. 1991; Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 13:627–631. DOI: 10.1002/hep.1840130403. PMID: 2010157.

6. Nam SW, Jung JJ, Bae SH, et al. 2007; Clinical outcomes of delayed clearance of serum HBsAG in patients with chronic HBV infection. Korean J Intern Med. 22:73–76. DOI: 10.3904/kjim.2007.22.2.73. PMID: 17616021. PMCID: PMC2687613.

7. Cornberg M, Lok AS, Terrault NA, Zoulim F. 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. 2020; Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J Hepatol. 72:539–557. DOI: 10.1016/j.jhep.2019.11.003. PMID: 31730789.

8. Chen YC, Sheen IS, Chu CM, Liaw YF. 2002; Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 123:1084–1089. DOI: 10.1053/gast.2002.36026. PMID: 12360470.

9. Kim JH, Lee YS, Lee HJ, et al. 2011; HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma. J Clin Gastroenterol. 45:64–68. DOI: 10.1097/MCG.0b013e3181dd558c. PMID: 20535028.

10. Choi J, Yoo S, Lim YS. 2021; Comparison of long-term clinical outcomes between spontaneous and therapy-induced HBsAg seroclearance. Hepatology. 73:2155–2166. DOI: 10.1002/hep.31610. PMID: 33131063.

11. Kim GA, Lim YS, An J, et al. 2014; HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 63:1325–1332. DOI: 10.1136/gutjnl-2013-305517. PMID: 24162593.

12. Yip TC, Wong GL, Wong VW, et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol. 2017; Oct. 6. doi: 10.1016/j.jhep.2017.09.018. DOI: 10.1016/j.jhep.2017.09.018.

13. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS. Taormina Workshop on Occult HBV Infection Faculty Members. 2019; Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 71:397–408. DOI: 10.1016/j.jhep.2019.03.034. PMID: 31004683.

14. Park Y, Lee JH, Sinn DH, et al. 2021; Risk and risk score performance of hepatocellular carcinoma development in patients with hepatitis B surface antigen seroclearance. Clin Transl Gastroenterol. 12:e00290. DOI: 10.14309/ctg.0000000000000290. PMID: 33433118. PMCID: PMC7803670.

15. Yip TC, Wong VW, Tse YK, et al. 2021; Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogueinduced hepatitis B surface antigen loss. Aliment Pharmacol Ther. 53:321–331.

16. Raffetti E, Fattovich G, Donato F. 2016; Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 36:1239–1251. DOI: 10.1111/liv.13142. PMID: 27062182.

17. Lee KJ, Han KH, Chun JY, et al. 1997; Natural history of chronic hepatitis type B throughout long-term follow-up. Korean J Gastroenterol. 29:343–351.